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LETTERS TO THE EDITOR 
Impregnation of sewing ring with antibiotics to 
avoid prosthetic valve endocarditis 
To the Editor: 
We read with great interest the original article by 
French and associates 1 regarding rifampicin impregna- 
tion of a mechanical valve sewing ring to prevent early 
endocarditis. Prosthetic valve endocarditis (PVE) is still 
a dangerous complication of cardiac operations. The 
reported incidence in the literature ranges from 1% to 
9% in patients undergoing heart valve replacement. 
Direct contamination during the operation has been 
suggested as a possible cause of early and late postop- 
erative PVE. Systemic antibiotic prophylaxis fails to 
achieve a sufficient antibiotic concentration in the 
sewing ring of the prosthesis, where PVE usually devel- 
ops. Another study by Karck and colleagues 2 showed a 
significant increase in the antibiotic concentration i  
the sewing ring after prosthetic valve pretreatment with 
a fibrin sealant compound. 
In 1971 we began pretreating prosthetic valves by 
immersing them in antibiotic solution before implanting 
them in patients. From 1971 to December 1991, 1262 
patients (504 men and 758 women, mean age 42.3 years, 
standard eviation 11.1; range 20 to 71 years) underwent 
heart valve replacement a our institution) 
Most of the patients (1250/1262; 99%) had elective 
operations. All patients but two received mechanical 
valves. A variety of systemic antibiotics were used for 
prophylaxis through the years at induction of anesthesia 
(penicillin, kanamycin, oxacillin, ampicillin, piperacil- 
lin, and ceftazidime). Before the prosthesis was low- 
ered, the sewing ring was immersed in 50 ml of saline 
solution containing the same antibiotic used at induc- 
tion. The sewing ring was generally soaked completely 
within 2 to 3 minutes. Parenteral antibiotic administra- 
tion was maintained uring the following 4 postopera- 
tive days. 
A complete follow-up was obtained in 964 patients 
(76.4%) by means of examination, questionnaires sent to 
their cardiologists, or telephone contact. 
The incidence of early PVE was only one case (0.08%) 
2 months after valve implantation, resulting from Staphy- 
lococcus epidermidis, and the patient underwent a success- 
ful second operation. 
Late PVE was observed in 12 cases (0.95%; Streptococ- 
cus, n = 5; Gram negative Haemophilus and Brucella, n = 
2; Candida, n = 1; indeterminate, n = 4). Seven patients 
were medically treated, none of whom died, but five 
underwent a second operation with two operative deaths 
(15%). 
In this large series of heart valve replacements he low 
incidence of early PVE can be attributed partially to the 
small number of emergency operations (1% only), but we 
believe that soaking the valve in antibiotic solution before 
implantation was helpful as well. 
Early PVE is almost always related to direct contami- 
nation during the operative procedure or to native valve 
endocarditis. The prosthesis sewing ring is usually the site 
of implantation of the etiologic agent because the low 
blood flow at the interface between the prosthesis and the 
valve anulus prevents adequate contact with the antibiotic 
present in the serum. 
We believe that increasing the concentration of anti- 
biotics in the valve sewing ring or vascular prosthesis is 
the correct philosophy to decrease this complication 
after heart valve implantation, and we congratulate 
French and colleagues for their idea to increase the 
concentration of antibiotics in the prosthetic tissue. 
Guglielmo M. Actis Dato, MD 
M. Cavaglia, MD 
G. A. Poletti, MD 
Italian Institution of Cardiac Surgery 
Via Genova, 4 
Torino 10126, Italy 
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12/8/81585 
Reply to the Editor." 
The authors of this letter have described a method of 
passively soaking all heart valves in a variety of solu- 
tions containing antibiotics before valve implantation. 
They have achieved a low incidence of early endocar- 
ditis in follow-up, which they recognize was incomplete. 
Although we agree that early postoperative endocar- 
ditis is due to perioperative or intraoperative contami- 
nation of the valve, our results failed to demonstrate 
rifampicin retention in vivo when we passively soaked 
the unsealed sewing ring. This is also implied in the 
article by Karck and associates, 1 who used a gentamicin 
derivative. We believe, with others, that rifampicin will 
bind to a protein sealant incorporated into the Dacron 
sewing ring, and in our study we found the best 
retention occurred when the sewing ring material was 
first sealed by being autoclaved in blood before being 
passively soaked in a solution of rifampicin. To do this 
adds significantly to the crossclamp time. We proposed 
145 
1 4 6 Letters to the Editor 
The Journal of Thoracic and 
Cardiovascular Surgery 
July 1997 
a protocol of using the technique for established cases 
of endocarditis, in which the incidence of prosthetic 
valve endocarditis highest. 
It is logical to consider the concept of impregnating 
all valves with antibiotics to minimize prosthetic valve 
endocarditis caused by perioperative contamination. 
We suggest hat to minimize crossclamp time but to 
provide adequate short-term local antibiotic levels in 
the valve sewing ring, a commercially available valve 
with a protein-sealed sewing ring could be soaked with 
rifampicin, similar to established techniques used in 
vascular surgery. 2'3 
B. G. French, FRACS 
M. F. O'Brien, FRACS 
Department of Cardiac Surgery 
The Prince Charles Hospital 
Brisbane 4032, Australia 
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12/8/81586 
Measurement of aortic diameter 
To the Editor." 
In the October 1996 issue of the Journal, Weinert and 
colleagues 1 give an elegant account of their measurements 
of aortic diameter by means of multiplane transesopha- 
geal echoeardiography. I have no complaints whatsoever 
concerning the excellence of the techniques described, but 
I have major problems with the anatomic structures that 
are purported to be measured. Apart from the fact that 
there is no ringlike structure 2' 3 supporting the hinge- 
points of the aortic valve leaflets (the so-called "anulus"), 
if the Chicago group makes measurements as they claim, 
then it is impossible for them to quantify the fullest 
diameter of the aortic root. The reason, of course, is that 
the aortic valve possesses three sinuses and leaflets and, 
even though the sinuses are rarely completely equal, 4
measuring from the basal attachment of the noncoronary 
leaflet o the basal attachment of the right coronary leaflet 
will always produce a chord of the outflow tract. Calcula- 
tions on the basis of the aortic root being a circle shows 
that measurements of the kind proposed underestimate 
the true diameter by a factor of 10% or more. The aortic 
root, of course, is not a true circle, but these geometric 
considerations are surely worthy of at least some discus- 
sion in studies of this kind. 
Robert H. Anderson, MD, FRCPath 
Imperial College School of Medicine 
Department of Paediatrics 
National Heart and Lung Institute 
Dovehouse St. 
London SW3 6LY, United Kingdom 
REFERENCES 
1. Weinert L, Karp R, Vignon P, Bales A, Lang RM. Feasibility 
of aortic diameter measurement bymultiplane transesopha- 
geal echocardiography for preoperative s lection and prepa- 
ration of homograft aortic valves. J Thorac Cardiovasc Surg 
1996;112:954-61. 
2. Anderson RH, Devine WA, Ho SY, Smith A, McKay R. The 
myth of the aortic annulus: the anatomy of the subaortic 
outflow tract. Ann Thorac Surg 1991;52:640-6. 
3. Sutton JP III, Ho SY, Anderson RH. The forgotten i terleaf- 
let triangles: a review of the surgical anatomy of the aortic 
valve. Ann Thorac Surg 1995;59:419-27. 
4. Vollebergh FEMG, Becker AE. Minor congenital variations 
of cusp size in tricuspid aortic valves: possible link with aortic 
stenosis. Br Heart J 1977;39:1006-11. 
[Response declined] 
12/8/81128 
Neuropsychologic outcome after normothermic 
cardiopulmonary bypass 
To the Editor: 
We agree happily with virtually all of Professor Trea- 
sure's commentary following our paper. 1 Indeed, our 
agreement is already explicit in the text. We planned and 
executed a randomized controlled study within pre-recog- 
nized externally applied constraints on numbers. We 
considered the available outcome measures and con- 
cluded that none would provide sufficient power to detect 
differences of any interesting size with the numbers avail- 
able. We welcome the consensus ofexperts that has taken 
place since our study was planned and completed, but 
know that the consensus i as much a way of sharing 
responsibility for error as a guaranteed pathway to truth. 
With the information available at the time, we made a 
prospective choice of an outcome measure that should 
logically have been more sensitive than existing ones and 
declared it to be our primary measure. No pilot data were 
available on this measure that could have informed pro- 
spective power calculations. It proved, in any case, to have 
enough power to detect an interesting difference with 95% 
confidence, although we made no secret of our doubt as to 
the clinical meaning of the difference. We identified the 
further analysis as being subsidiary, to inform further 
studies on the problems of this nature. 
Nowhere did we use our results to draw inferences 
about stroke rate. Nowhere did we draw any conclusions 
about safety. Our concluding sentence remarked that our 
results, and the absence of any separate demonstration f 
benefit, provided little incentive to recommend the rou- 
tine use of normothermic systemic perfusion (instead of 
